JP2015526487A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526487A5
JP2015526487A5 JP2015528857A JP2015528857A JP2015526487A5 JP 2015526487 A5 JP2015526487 A5 JP 2015526487A5 JP 2015528857 A JP2015528857 A JP 2015528857A JP 2015528857 A JP2015528857 A JP 2015528857A JP 2015526487 A5 JP2015526487 A5 JP 2015526487A5
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
pharmaceutically acceptable
mesomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015528857A
Other languages
English (en)
Japanese (ja)
Other versions
JP6262733B2 (ja
JP2015526487A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2013/082273 external-priority patent/WO2014036897A1/zh
Publication of JP2015526487A publication Critical patent/JP2015526487A/ja
Publication of JP2015526487A5 publication Critical patent/JP2015526487A5/ja
Application granted granted Critical
Publication of JP6262733B2 publication Critical patent/JP6262733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015528857A 2012-09-04 2013-08-26 イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 Active JP6262733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210323870.3 2012-09-04
CN201210323870 2012-09-04
PCT/CN2013/082273 WO2014036897A1 (zh) 2012-09-04 2013-08-26 咪唑啉类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2015526487A JP2015526487A (ja) 2015-09-10
JP2015526487A5 true JP2015526487A5 (OSRAM) 2017-12-21
JP6262733B2 JP6262733B2 (ja) 2018-01-17

Family

ID=50236528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528857A Active JP6262733B2 (ja) 2012-09-04 2013-08-26 イミダゾリン誘導体、その製造法、およびそれらの医薬への適用

Country Status (22)

Country Link
US (2) US9586947B2 (OSRAM)
EP (1) EP2894151B1 (OSRAM)
JP (1) JP6262733B2 (OSRAM)
KR (1) KR102189940B1 (OSRAM)
CN (1) CN103958480B (OSRAM)
AU (1) AU2013312587B2 (OSRAM)
BR (1) BR112015004637B1 (OSRAM)
CA (1) CA2883545C (OSRAM)
CY (1) CY1123649T1 (OSRAM)
DK (1) DK2894151T3 (OSRAM)
ES (1) ES2835248T3 (OSRAM)
HR (1) HRP20202050T1 (OSRAM)
HU (1) HUE052904T2 (OSRAM)
LT (1) LT2894151T (OSRAM)
MX (1) MX368844B (OSRAM)
PT (1) PT2894151T (OSRAM)
RS (1) RS61242B1 (OSRAM)
RU (1) RU2639145C2 (OSRAM)
SI (1) SI2894151T1 (OSRAM)
SM (1) SMT202000672T1 (OSRAM)
TW (1) TWI617546B (OSRAM)
WO (1) WO2014036897A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2639145C2 (ru) * 2012-09-04 2017-12-20 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные оксотиоимидазолидина, способы их получения и их применение в медицине в качестве ингибиторов андрогенного рецептора
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11352351B2 (en) * 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
RU2018105094A (ru) * 2015-07-13 2019-08-14 Арвинас, Инк. Модуляторы протеолиза на основе аланина и связанные с ними способы применения
WO2017041622A1 (zh) * 2015-09-10 2017-03-16 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的结晶形式及其制备方法
CN106518773A (zh) * 2015-09-10 2017-03-22 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的结晶形式及其制备方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
KR20180109991A (ko) * 2016-02-19 2018-10-08 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이미다졸린 유도체를 함유하는 약학적 조성물
CA3030181A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
WO2018009694A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Thiohydantoin androgen receptor antagonists for the treatment of cancer
US20200000776A1 (en) 2017-02-13 2020-01-02 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
CN109912509B (zh) * 2017-12-13 2021-02-26 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的晶型及其制备方法
CN110684046B (zh) * 2018-07-06 2023-05-12 江苏恒瑞医药股份有限公司 一种新的咪唑啉类衍生物的制备方法
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
AU2019344897B2 (en) 2018-09-18 2024-01-18 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
WO2020083187A1 (zh) * 2018-10-22 2020-04-30 江苏恒瑞医药股份有限公司 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途
FI3897636T3 (fi) * 2018-12-19 2025-02-03 Celgene Corp Substituoituja 3-((3-aminofenyyli)amino)piperidiini-2,6-dioniyhdisteitä, niiden koostumuksia ja menetelmiä niillä annettavia hoitoja varten
KR102864064B1 (ko) 2018-12-19 2025-09-24 셀진 코포레이션 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
CN113929628A (zh) * 2020-06-29 2022-01-14 江苏恒瑞医药股份有限公司 一种咪唑啉衍生物的制备方法
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
RU2304140C2 (ru) 2001-12-27 2007-08-10 Дайити Фармасьютикал Ко., Лтд. ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ β-АМИЛОИДНОГО БЕЛКА
AU2003279442A1 (en) * 2002-10-04 2004-04-23 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
CN101676270A (zh) 2004-09-09 2010-03-24 中外制药株式会社 新型四氢咪唑衍生物及其用途
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
RS52274B2 (sr) * 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
CA2838448A1 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
EA019647B1 (ru) 2009-02-10 2014-05-30 Астразенека Аб ПРОИЗВОДНЫЕ ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
WO2011008543A2 (en) 2009-06-29 2011-01-20 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
US8383651B2 (en) 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
WO2012015723A1 (en) 2010-07-26 2012-02-02 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
WO2012050868A1 (en) 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
UA113501C2 (xx) 2010-11-03 2017-02-10 Пестицидні композиції і пов'язані з ними способи
CA2829322C (en) 2011-03-10 2017-01-10 Suzhou Kintor Pharmaceuticals, Inc. Substituted thioimidazolidinone androgen receptor antagonists and uses thereof
RU2639145C2 (ru) * 2012-09-04 2017-12-20 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные оксотиоимидазолидина, способы их получения и их применение в медицине в качестве ингибиторов андрогенного рецептора

Similar Documents

Publication Publication Date Title
JP2015526487A5 (OSRAM)
RU2015110122A (ru) Производные имидазолина, способы их получения и их применение в медицине
TWI674258B (zh) Dna烷化劑
JP2017533968A5 (OSRAM)
WO2017195216A4 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP2007509116A5 (OSRAM)
JP2017526727A5 (OSRAM)
JP2013518106A5 (OSRAM)
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
JP2014185188A (ja) フェニルおよびベンゾジオキシニル置換インダゾール誘導体
JP2011116780A5 (OSRAM)
CA2727378A1 (en) New co-crystal compound of rivaroxaban and malonic acid
JP2012522847A5 (OSRAM)
IL228072A (en) Quinazoline compound is converted to alkyl and methods of use
JP2018527328A (ja) 置換3−(3−アニリノ−1−シクロヘキシル−1h−ベンズイミダゾール−5−イル)プロパン酸誘導体を調製する方法
JP2013521301A5 (OSRAM)
WO2014031755A1 (en) Fendiline derivatives and methods of use thereof
JP2019535825A5 (OSRAM)
RU2012126112A (ru) Соединение, некоторые его новые формы, фармацевтические композиции на его основе и способы получения и применения
JP2009531363A5 (OSRAM)
JP5575357B2 (ja) 組織因子産生抑制剤
AU2015367540B2 (en) Substituted Pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
JP2018516873A5 (OSRAM)
RU2013125756A (ru) Твердые формы (s)-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропановой кислоты